Impact of common risk factors of fibrosis progression in chronic hepatitis C. (Q41741892)

8 October 2017

Impact of common risk factors of fibrosis progression in chronic hepatitis C. (English)

1 reference

8 October 2017

6

1 reference

8 October 2017

7

1 reference

8 October 2017

18

1 reference

8 October 2017

V Suppiah

11

0 references

Laurent Abel

object named as

L Abel

22

0 references

Bertrand Nalpas

object named as

B Nalpas

19

0 references

Thierry Poynard

20

object named as

T Poynard

1 reference

8 October 2017

1

S Rüeger

1 reference

8 October 2017

P-Y Bochud

2

1 reference

8 October 2017

J-F Dufour

3

1 reference

8 October 2017

B Müllhaupt

4

1 reference

8 October 2017

D Semela

5

1 reference

8 October 2017

A Cerny

8

1 reference

8 October 2017

R Malinverni

9

1 reference

8 October 2017

D R Booth

10

1 reference

8 October 2017

J George

12

1 reference

8 October 2017

L Argiro

13

1 reference

8 October 2017

P Halfon

14

1 reference

8 October 2017

M Bourlière

15

1 reference

8 October 2017

A H Talal

16

1 reference

8 October 2017

I M Jacobson

17

1 reference

8 October 2017

S Pol

21

1 reference

8 October 2017

Z Kutalik

23

1 reference

8 October 2017

F Negro

24

1 reference

8 October 2017

language of work or name

English

0 references

publication date

11 September 2014

1 reference

8 October 2017

1 reference

8 October 2017

64

1 reference

8 October 2017

1605-1615

1 reference

8 October 2017

10

1 reference

Epidemiology and natural history of HCV infection.

8 October 2017

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Environmental factors as disease accelerators during chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

A better coefficient of determination for genetic profile analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Quantifying and correcting for the winner's curse in genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Cigarette smoking and hepatic lesions in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Impact of smoking on histological liver lesions in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Alcohol drinking and all cancer mortality: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Is genotype 3 of the hepatitis C virus the new villain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Phagocytosis and clearance of apoptotic cells is mediated by MER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Polyfunctional type-1, -2, and -17 CD8⁺ T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

Use and misuse of population attributable fractions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2014-306997

10.1136/GUTJNL-2014-306997

21 January 2018

Identifiers

DOI

1 reference

8 October 2017

1 reference